Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize Tlando, its oral testosterone replacement therapy, in the Gulf Cooperation Council countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain and Oman. Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink and, following marketing authorizations in individual GCC countries, Lipocine will supply the drug Tlando to Pharmalink at an agreed transfer price. Pharmalink will have exclusive rights to Tlando across the GCC region and will be responsible for the promotion, distribution and sales of the product in the territory.
First published on DeVlieg – the ultimate source for real-time, market-moving financial news. Try now >>
See insiders’ hot stocks on TipRanks >>
Read more about LPCN:
